相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study
Kadalraja Raghavan et al.
IBRO NEUROSCIENCE REPORTS (2023)
Beneficial effects of novel aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study
Kadalraja Raghavan et al.
BIOMEDICINE & PHARMACOTHERAPY (2022)
Beneficial effects of 1,3-1,6 β-glucans produced by Aureobasidium pullulans on non-esterified fatty acid levels in diabetic KKAy mice and their potential implications in metabolic dysregulation
Nobunao Ikewaki et al.
JOURNAL OF DIABETES AND METABOLIC DISORDERS (2022)
Hepatoprotective Effects of Aureobasidium pullulans Derived ? 1,3-1,6 Glucans in a Murine Model of Non-alcoholic Steatohepatitis
Nobunao Ikewaki et al.
JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY (2022)
Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential applications in human health and disease
Senthilkumar Preethy et al.
BMJ OPEN GASTROENTEROLOGY (2022)
Epigenetic modifications in muscle regeneration and progression of Duchenne muscular dystrophy
Anna Rugowska et al.
CLINICAL EPIGENETICS (2021)
Inflammation in Duchenne Muscular Dystrophy-Exploring the Role of Neutrophils in Muscle Damage and Regeneration
Ankita Tulangekar et al.
BIOMEDICINES (2021)
Current Pharmacological Strategies for Duchenne Muscular Dystrophy
Shanshan Yao et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis
Erik Landfeldt et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2020)
Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis
Salvatore Crisafulli et al.
ORPHANET JOURNAL OF RARE DISEASES (2020)
Identification of plasma interleukins as biomarkers for deflazacort and omega-3 based Duchenne muscular dystrophy therapy
Samara Camacari de Carvalho et al.
CYTOKINE (2018)
Long-Term Morpholino Oligomers in Hexose Elicits Long-Lasting Therapeutic Improvements in mdx Mice
Gang Han et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy
Sandra Murphy et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)
Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents
Alan S. Robertson et al.
NEUROMUSCULAR DISORDERS (2017)
Potential Therapeutic Action of Adiponectin in Duchenne Muscular Dystrophy
Michel. Abou-Samra et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Impaired regenerative capacity and lower revertant fibre expansion in dystrophin-deficient mdx muscles on DBA/2 background
Merryl Rodrigues et al.
SCIENTIFIC REPORTS (2016)
Dystrophin and utrophin double knockout dystrophic mice exhibit a spectrum of degenerative musculoskeletal abnormalities
Christian Isaac et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2013)
Daily Treatment with SMTC1100, a Novel Small Molecule Utrophin Upregulator, Dramatically Reduces the Dystrophic Symptoms in the mdx Mouse
Jonathon M. Tinsley et al.
PLOS ONE (2011)
Smooth muscle-specific dystrophin expression improves aberrant vasoregulation in mdx mice
Kaori Ito et al.
HUMAN MOLECULAR GENETICS (2006)
Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression
E Lutgens et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2002)
Resolution of skeletal muscle inflammation in mdx dystrophic mouse is accompanied by increased immunoglobulin and interferon-γ production
J Lagrota-Candido et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2002)